Other pharmacological dyslipidemia treatment options for raising HDL-cholesterol

被引：0

作者：

Frias Vargas, Manuel ^{[1
]}

Peraira Moral, Juan Roberto ^{[2
]}

Lopez Serrano, Beatriz ^{[1
]}

机构：

[1] CS Maria Angeles Lopez Gomez, Madrid, Spain

[2] Hosp Infanta Sofia, Secc Cardiol, Madrid, Spain

来源：

ATENCION PRIMARIA | 2010年 / 42卷 / 08期

关键词：

THIAZOLIDINEDIONES;

D O I：

10.1016/j.aprim.2010.03.012

中图分类号：

R1 [预防医学、卫生学];

学科分类号：

1004 ; 120402 ;

摘要：

引用

页码：442 / 442

页数：1

共 6 条

[1] Increased high-density lipoprotein cholesterol predicts the pioglitazone-mediated reduction of carotid intima-media thickness progression in patients with type 2 diabetes mellitus
Davidson, Michael
Meyer, Peter M.
Haffner, Steven
Feinstein, Steven
D'Agostino, Ralph
Kondos, George T.
Perez, Alfonso
Chen, Zhen
Mazzone, Theodore
[J]. CIRCULATION, 2008, 117 (16) : 2123 - 2130
[2] Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events):: a randomised controlled trial
Dormandy, JA
Charbonnel, B
Eckland, DJA
Erdmann, E
Massi-Benedetti, M
Kmoules, IK
Skene, AM
Tan, MH
Lefébvre, PJ
Murray, GD
Standl, E
Wilcox, RG
Wlhelmsen, L
Betteridge, J
Birkeland, K
Golay, A
Heine, RJ
Korányi, L
Laakso, M
Mokán, M
Norkus, A
Pirags, V
Podar, T
Scheen, A
Scherbaum, W
Schernthaner, G
Schmitz, O
Skrha, J
Smith, U
Taton, J
[J]. LANCET, 2005, 366 (9493) : 1279 - 1289
[3] KAUL B, 2010, CIRCULATION, DOI DOI 10.1161/CIR.0B013E3181D334114
[4] Thiazolidinediones in type 2 diabetes: A cardiology perspective
Khanderia, Ujjaini
Pop-Busui, Rodica
Eagle, Kim A.
[J]. ANNALS OF PHARMACOTHERAPY, 2008, 42 (10) : 1466 - 1474
[5] Therapeutic drug option for dyslipaemia
Maiques Galan, Antonio
Brotons Cuixart, Carlos
[J]. ATENCION PRIMARIA, 2010, 42 (02): : 115 - 120
[6] Drug therapy: Thiazolidinediones
Yki-Jarvinen, H
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (11) : 1106 - 1118